BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

講師

免疫功坊股份有限公司

 

Company Info

Name /Immunwork, Inc.

Address /C520, No. 99, Lane 130, Sec. 1, Academia Rd., Nangang District, Taipei, Taiwan

Website /www.immunwork.com

Presenter

Name /Kun-Po Li

Title /Manager of External Collaboration and Clinical Development

Email /kunpo.li@immunwork.com

Telephone /02-2651-2268

Fax /

Mobile /

Company Type

Biotechnology

About the Company

Immunwork, Inc. is a privately-held biotech company focuses on the research, development, and commercialization of new drugs to fulfill unmet medical needs. Based in Taipei and with the founding members affiliated with Academia Sinica, we have invented and developed proprietary technology platforms and drug candidates which could provide novel drug designing processes and help the patients in need. Our unique “multi-arm linker” platform could combine different drug moieties together and generate novel drug molecules. We are looking forward to bringing the drug candidates to the next stage, as well as using the technology platform to generate additional novel drugs.

Brief Description of main products or services

Immunwork’s unique technology platform allows us to design and generate novel “T-E” drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. In the majority of our T-E drugs, different drug moieties are conjugated together by our proprietary “multi-arm linkers” and generate novel, multi-functional, drug molecules. Immunwork has drug candidates including antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage, and all of them have improved efficacy, safety, and/or dosage formats. The target indications include multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. These drug candidates could fulfill the unmet medical needs and improve the quality of life for patients. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.

The technology platforms and drug candidates are invented and developed by Immunwork. More than 60 patents have been granted worldwide, and more than 50 patent applications are in progress.

Contact Person

Name /Kun-Po Li

Email /kunpo.li@immunwork.com

Phone /02-2651-2268